Keros Therapeutics, Inc. (KROS)
9.36
-0.09
(-0.95%)
USD |
NASDAQ |
Nov 06, 16:00
9.315
-0.04
(-0.48%)
After-Hours: 20:00
Keros Therapeutics Enterprise Value : -56.30M for Nov. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 06, 2026 | -56.30M |
| November 05, 2026 | -54.52M |
| November 04, 2026 | -27.15M |
| November 03, 2026 | -27.15M |
| November 02, 2026 | -28.54M |
| October 30, 2026 | -22.99M |
| October 29, 2026 | -16.64M |
| October 28, 2026 | -11.69M |
| October 27, 2026 | -15.36M |
| October 26, 2026 | -17.24M |
| October 23, 2026 | -18.23M |
| October 22, 2026 | -16.84M |
| October 21, 2026 | -20.21M |
| October 20, 2026 | -15.85M |
| October 19, 2026 | -22.59M |
| October 16, 2026 | -30.52M |
| October 15, 2026 | -21.80M |
| October 14, 2026 | -22.79M |
| October 13, 2026 | -19.22M |
| October 12, 2026 | -11.69M |
| October 09, 2026 | -4.947M |
| October 08, 2026 | -11.09M |
| October 07, 2026 | -19.62M |
| October 06, 2026 | -23.58M |
| October 05, 2026 | -13.47M |
| Date | Value |
|---|---|
| October 02, 2026 | -16.64M |
| October 01, 2026 | -18.63M |
| September 30, 2026 | -15.85M |
| September 29, 2026 | -20.02M |
| September 28, 2026 | -18.23M |
| September 25, 2026 | -11.49M |
| September 24, 2026 | -12.88M |
| September 23, 2026 | -11.29M |
| September 22, 2026 | -9.309M |
| September 21, 2026 | -14.27M |
| September 18, 2026 | -20.02M |
| September 17, 2026 | -16.64M |
| September 16, 2026 | -28.94M |
| September 15, 2026 | -20.41M |
| September 14, 2026 | -19.62M |
| September 11, 2026 | -22.20M |
| September 10, 2026 | -20.41M |
| September 09, 2026 | -17.64M |
| September 08, 2026 | -20.41M |
| September 04, 2026 | -17.44M |
| September 03, 2026 | -21.60M |
| September 02, 2026 | -19.22M |
| September 01, 2026 | -22.39M |
| August 31, 2026 | -22.20M |
| August 28, 2026 | -23.19M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agios Pharmaceuticals, Inc. | 1.167B |
| Viking Therapeutics, Inc. | 2.718B |
| Protagonist Therapeutics, Inc. | 7.766B |
| ACADIA Pharmaceuticals, Inc. | 2.735B |
| Alnylam Pharmaceuticals, Inc. | 20.29B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -28.71M |
| Total Expenses (Quarterly) | 28.71M |
| EPS Diluted (Quarterly) | -1.45 |
| Earnings Yield | -39.53% |
| Normalized Earnings Yield | -39.50 |